ReviewThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2025
High Prevalence of
Review in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Primary research articles on PfHRP2/3 gene deletions (2000-2025) were retrieved from PubMed, Science Direct, and Google Scholar. Eligible studies were systematically searched between May 3 2025, and June 2, 2025. The quality of the included studies was assessed using the Newcastle-Ottawa Scale. Data analysis was performed using STATA Version 17, employing a random effects model. Heterogeneity among studies was evaluated using the Results: A total of 932 studies were initially identified, among these 18 studies were selected for full-text review. After excluding 7 studies, 11 articles were included in the meta-analysis. The overall pooled prevalence of PfHRP2/3 gene deletions was 35.64% (95% CI: 21.43, 49.85). Specifically, the pooled prevalence of PfHRP2 and PfHRP3 gene deletions was 8.48% (95% CI: 0.96, 16.01) and 23.74% (95% CI: 12.16, 35.32), respectively, while concurrent deletions of both genes account for 8.14% (95% CI: 0.67, 15.61). Conclusion: This systematic review and meta-analysis revealed a high prevalence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.